<DOC>
	<DOCNO>NCT00002711</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining radiation therapy chemotherapy may kill tumor cell . PURPOSE : Phase I trial study effectiveness combination chemotherapy radiation therapy treat patient cancer esophagus .</brief_summary>
	<brief_title>Combination Chemotherapy Radiation Therapy Treating Patients With Cancer Esophagus</brief_title>
	<detailed_description>OBJECTIVES : I . Estimate maximum tolerate dose recommend phase II dose paclitaxel ( TAX ) administer 96-hour intravenous infusion weekly fix dose intravenous cisplatin ( CDDP ) concurrent radiotherapy patient localized esophageal cancer . II . Estimate response rate patient treat 2 course TAX/CDDP induction chemotherapy complete response rate patient treat TAX/CDDP concurrent radiotherapy . III . Describe toxic effect TAX/CDDP prior radiotherapy . IV . Describe pharmacokinetics TAX continuous infusion ( CI ) 96 hour . V. Evaluate , flow cytometry , ability CI TAX block esophageal cancer cell G2-M phase cell cycle . OUTLINE : After MTD TAX reach Part A , new patient enter Part B . The following acronym use : CDDP Cisplatin , NSC-119875 EBRT External-beam radiotherapy TAX Paclitaxel ( Bristol-Myers ) , NSC-125973 PART A : Radiotherapy plus 2-Drug Combination Chemotherapy . EBRT use megavoltage equipment ( &gt; /= 10 MV recommend ; electron boost allow subclavicular fossa ) ; plus TAX/CDDP . PART B : 2-Drug Combination Induction Chemotherapy follow Radiotherapy plus 2-Drug Combination Chemotherapy . TAX/CDDP ; follow EBRT Part A ; plus TAX/CDDP . PROJECTED ACCRUAL : At least 3 patients/dose enter Part A ( 24 patient ) 3-6 patient Part B .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm epidermoid carcinoma adenocarcinoma esophagus eligible potentially curative radiotherapy Disease one follow category : Newly diagnose Locoregional failure prior resection curative intent Positive microscopic margin palliative resection gross disease Disease clinically limit esophagus T 14 , N , M0 Gastroesophageal junction tumor allow No positive pleural , pericardial , peritoneal cytology No tracheobronchial invasion bronchoscopy , include tracheoesophageal fistula PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Hematopoietic : WBC 4,000/mm3 Platelet count least 150,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 65 mL/min per 1.73 square meter Cardiovascular : No NYHA class 3/4 status No cerebral vascular disease No hypertension Other : No severe uncontrolled diabetes No uncontrolled infection No medical condition precludes treatment No mental status abnormality preclude comprehension compliance treatment No active cancer arise another primary site basal cell carcinoma skin situ cervical carcinoma PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>stage I esophageal cancer</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>squamous cell carcinoma esophagus</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
</DOC>